Hematopoetic Stem Cell Transplantation in Children

Year 2022, Volume: 39 Issue: 4, 1270 - 1276, 29.10.2022

Canan  Albayrak

Abstract

Bone marrow transplantation is now called hematopoietic stem cell transplantation (HSCT) because, apart from bone marrow, peripheral blood and umbilical cord blood can also be used as stem cell sources. HSCT can be performed in three ways. One is autologous stem cell transplantation. The other is allogeneic stem cell transplantation. Another type of transplantation applied in recent years is haploidentic transplantation. More than 20% of all allogeneic HSCTs are performed in patients under 20 years of age. HSCT has become a well-established lifesaving treatment procedure for many patients with hematological malignancies, hemoglobinopathies, inborn errors, or bone marrow failure syndromes. HSCT is now integrated as an essential part in many treatment concepts and protocols. HSCT is a treatment that provides an increase in success compared to other treatments when it is performed in suitable patients and in accordance with the standards. Selection of the appropriate transplant type, appropriate donor, appropriate preparation regimen, and close monitoring of complications are essential.

Keywords

hematopoietic stem cell transplantation, child, indication, graft versus host disease

References

• 1. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015; 50(8): 1037-56.
• 2. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(11): 1863-1869.
• 3. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957; 257: 491-6.
• 4.https://www.saglikaktuel.com/d/file/11249,pediatrik-endikasyon-listesipdf.pdf
• 5. Kansoy S. TPHD Ulusal Pediatrik KİT Online Veritabanı, 2018
• 6. Yesilipek MA, Uygun V, Kupesiz A, G Karasu, G Ozturk, M Ertem, et al. Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience. Bone Marrow Transplant. 2022; 57: 760–767.
• 7. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, et al. Eurocord Transplant Group. Re¬lated umbilical cord blood transplant in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137-43.
• 8. Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer open; 2019.
• 9. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/venoocclusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018; 53: 138–45.